Pharmasset Announces All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated

Pharmasset, Inc. VRUS announced today the initiation of a Phase 2a trial investigating the combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and BMS-790052, Bristol-Myers Squibb Company's BMY NS5A replication complex inhibitor, for the treatment of chronic hepatitis C. This trial is the result of a clinical collaboration agreement between Pharmasset and Bristol-Myers Squibb announced in January 2011.